UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

 

 

September 24, 2009

--------------------------------------------

Date of Report (Date of earliest event reported) 

 

ELITE PHARMACEUTICALS INC.

--------------------------------------------------------

(Exact name of registrant as specified in its charter)

 

 

Delaware

001-15697

22-3542636

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

 

165 Ludlow Avenue, Northvale NJ 07647

------------------------------------------------------------------

(Address of principal executive offices)

 

(201) 750-2646

---------------------------

(Company’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

 

 

Item 5.02.

 

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On September 24, 2009 Dr. Melvin H. Van Woert resigned from the board of directors of Elite Pharmaceuticals, Inc.

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

September 30, 2009

 

 

ELITE PHARMACEUTICALS, INC.

 

 

 

 

 

By:

/s/ Chris Dick

 

 

Chris Dick

 

 

President and Chief Operating Officer